Test Price
4,500 AED✅ Home Collection Available
Cancer Targeted Gene Panel: Lung with PD‑L1 (DAKO) Test in UAE – 4500 AED
Executive Summary & Core Metrics
Executive Summary
The Cancer Targeted Gene Panel for Lung with PD‑L1 (DAKO) delivers a comprehensive molecular profile combining next-generation sequencing (NGS), fluorescence in situ hybridisation (FISH), and immunohistochemistry (IHC) in a single, clinically actionable report. Designed for non‑small cell lung cancer (NSCLC) patients, the assay identifies >50 key driver mutations, gene rearrangements, and PD‑L1 tumour proportion score (TPS) to guide targeted therapy and immunotherapy decisions.
Test Overview & Methodology
The Cancer Targeted Gene Panel: Lung with PD‑L1 (DAKO) integrates three orthogonal platforms – NGS for nucleic acid mutations, FISH for large rearrangements, and DAKO 22C3 pharmDx IHC for PD‑L1 expression. This tri‑modal approach provides a complete genomic and immune landscape essential for optimal NSCLC treatment planning. The assay is performed on archival formalin‑fixed, paraffin‑embedded (FFPE) tissue blocks or biopsy slides, requiring a minimum tumour content of 10%.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | Tri‑modal: NGS + FISH + IHC (DAKO validated) | Single‑modality (NGS only or IHC only) |
| Methodology | LC‑MS/MS quality‑controlled; ISO 15189 aligned | Conventional NGS without integrated PD‑L1 |
| Turnaround | 10–14 business days from receipt of adequate specimen | 14–21 days, highly variable |
| Coverage | >50 key lung cancer genes + PD‑L1 score (TPS) | Limited panel, often omitting PD‑L1 |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“Interpretation of the lung cancer gene panel requires integration of molecular findings with the patient’s complete clinical history. The identification of actionable alterations such as EGFR mutations or PD‑L1 expression offers significant therapeutic opportunities. It is essential that results are reviewed by the treating oncologist to align with the patient’s overall treatment strategy. Our laboratory adheres to rigorous quality controls to ensure every report is clinically reliable.”
Medication Advisory
Do not discontinue or modify any prescribed targeted therapy or immunotherapy without consulting your treating physician. Dose adjustments are only made after expert analysis of these molecular results.
Safety & Exclusion Criteria
- Sample adequacy: FFPE blocks with less than 10% tumour content cannot be processed; request a re‑biopsy if tumour area is insufficient.
- Decay: Tissue blocks older than 5 years may yield degraded DNA/RNA – a fresh biopsy is strongly recommended.
- Drug interference: Any last‑dose of heparin or DNA‑damaging chemotherapy within 48 hours of biopsy should be disclosed.
Patient FAQ & Clinical Guidance
1. What is the cancer targeted gene panel for lung with PD‑L1 test?
It is a comprehensive genomic test identifying key mutations, gene fusions, and PD‑L1 expression to guide personalised lung cancer therapy. The result includes a report of all detected alterations and recommended targeted therapies.
2. How is the test performed and what do I need to provide?
The laboratory uses NGS, FISH and IHC on your existing FFPE tissue block. You must submit a copy of the histopathology report, biopsy site information, clinical history, and a completed NGS requisition form. Our courier will retrieve the specimen securely.
3. What is the cost and can I use insurance?
The price is 4500 AED. We directly verify billing with major insurers – simply message us on WhatsApp at +971 54 548 8731 to initiate the process.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
DNA Labs UAE operates under DHA Facility License Number 1143. All clinical data handling, storage, and transmission strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and safety protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Cancer Targeted Gene Panel: Lung with PD‑L1 (DAKO) |
| Price (AED) | 4,500 |
| Turnaround Time | 10–14 business days from receipt of adequate specimen |
| Sample Type / Matrix | Archival FFPE Tissue Block or Biopsy Slides |
| Methodology Used | Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC) with DAKO 22C3 pharmDx |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of lung, unspecified) |
| LOINC Code | 96539-6 (Lung cancer somatic mutations panel) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians